CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target

Positive
AI Analysis

Summary

Guggenheim initiates coverage of Rapport Therapeutics with a Buy rating and $65 price target.

Importance:2/10
Sentiment:
0.60
analyst_initiationprice_targetequity_research
Related Companies

Read the original article

Published by yahoo_finance on October 6, 2026 10:00 AM

Read Original